Rheumatoide

Pfizer has received the US Food and Drug Administration (FDA) approval for its Xeljanz XR (tofacitinib citrate) extended-release tablets for the treatment of rheumatoid arthritis (RA).

Xeljanz XR is the first and only once-daily oral RA treatment in its Janus kinase (JAK) class inhibitors.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The 11mg Xeljanz XR tablets can now be used once in a day to treat moderate to severe RA in patients who have had an inadequate response or intolerance to methotrexate, the company said.

This oral JAK inhibitor does not require injections or infusions and can be taken with or without methotrexate.

Pfizer global innovative pharmaceuticals business inflammation and immunology category development lead Michael Corbo said: "The introduction of the first and only once-daily oral JAK inhibitor for RA, Xeljanz XR, builds upon Pfizer’s tradition of developing patient-centred therapies."

See Also:

"The introduction of the first and only once-daily oral JAK inhibitor for RA, Xeljanz XR, builds upon Pfizer’s tradition of developing patient-centred therapies."

Xeljanz XR is approved in more than 45 countries for the treatment of moderate to severe RA as a second-line therapy, after failure of one or more disease-modifying anti-rheumatic drugs (DMARDs).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The use of Xeljanz XR in combination with biologic DMARDs or potent immunosuppressants, such as azathioprine and cyclosporine is not recommended.

University of Texas Southwestern Medical Centre department of internal medicine clinical professor Dr Roy Fleischmann said: "The availability of Xeljanz XR provides physicians with a new treatment option for people with RA who may prefer an oral once-daily treatment."

The efficacy and safety of Xeljanz has been studied in nearly 6,200 patients with moderate to severe RA, amounting to more than 19,400 patient-years of drug exposure in the global clinical development programme.

Image: X-ray of the hand in rheumatoid arthritis. Photo: courtesy of Bernd Brägelmann.